Sophie Labrecque, MSc, RN, CIC Lynda Mack, MSN, RN, CCRN, CIC Moira Quinn, BSN, RN, CIC Georgetta Rinck, MPH, RN, CIC Teresa Rowland, BSN, RN Rita Sussner, BSN, RN, CIC Westchester Medical CenterValhalla, NY
The FDA is warning healthcare providers about a newly discovered potential drug interaction related to the investigational antiviral drug remdesivir, which has received emergency use authorization for the treatment of hospitalized COVID-19 patients with severe disease. Based on a recently completed non-clinical laboratory study, the FDA is revising the fact sheet for healthcare providers that accompanies the […]
News
More StoriesWhat’s New at APIC
5 Second Rule Show: Episode 9: “Behind the 5 Second Rule”
APIC President on the Public Health Impact of Racism
APIC Publishes Implementation Guide on NV-HAP
5 Second Rule Show: Episode 8 “Creating a Healthier World: It’s In Your Clean Hands”
Publications
Prevention Strategist—Summer 2020
05/28/2020
Highlights:
- Coronavirus disease (COVID-19) timeline, December 31, 2019 – April 3, 2020
- APIC’s ongoing COVID-19 response
- Applying and using APIC’s Competency Model for the Infection Preventionist
American Journal of Infection Control—June 2020
05/29/2020
Highlights:
- A qualitative study on the psychological experience of caregivers of COVID-19 patients
- Examining the inclusion of patients and their family members in infection prevention and control policies and guidelines across Bangladesh, Indonesia, and South Korea
- How much is adequate staffing for infection control? A deterministic approach through the lens of Workload Indicators of Staffing Need
- High consequence infectious diseases training using interprofessional simulation and TeamSTEPPS
- Impact of an educational program on reducing healthcare-associated meningitis or ventriculitis in the neurosurgical intensive care unit